Andrzej Andraczke - 21 Sep 2023 Form 4/A - Amendment Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Reporting relationship: Director
Issuer ticker: CNSP
Reported as of: 21 Sep 2023
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 12 Oct 2023, 18:00:06 UTC
Original report date: 25 Sep 2023
Prior SEC filing: 16 Jul 2021
Source filing: View source filing
Reporting owner signature: /s/ Christopher Downs, Attorney-in-fact

Key filing fact

Andrzej Andraczke filed Form 4/A - Amendment for CNS Pharmaceuticals, Inc. (CNSP) on 12 Oct 2023.

Key facts

This page summarizes Andrzej Andraczke's Form 4/A - Amendment filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Oct 2023, 18:00.

Change

Previous filing in this sequence was filed on 16 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CNSP transaction Derivative

Option to purchase common stock

Award

Transaction value
Shares: +39,475
Change %: +663%
Price
Shares after: 45,428
Date: 21 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,475
Exercise price: $1.09
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Footnote F2

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

SEC remarks

This amendment is being filed solely to correct the number of shares of common stock underlying the reported option, and total number of derivative securities owned following the reported transaction.